These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 31393852)
21. Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. Sos BC; Harris C; Nordstrom SM; Tran JL; Balázs M; Caplazi P; Febbraio M; Applegate MA; Wagner KU; Weiss EJ J Clin Invest; 2011 Apr; 121(4):1412-23. PubMed ID: 21364286 [TBL] [Abstract][Full Text] [Related]
22. Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance. Shi SY; Martin RG; Duncan RE; Choi D; Lu SY; Schroer SA; Cai EP; Luk CT; Hopperton KE; Domenichiello AF; Tang C; Naples M; Dekker MJ; Giacca A; Adeli K; Wagner KU; Bazinet RP; Woo M J Biol Chem; 2012 Mar; 287(13):10277-10288. PubMed ID: 22275361 [TBL] [Abstract][Full Text] [Related]
23. The role of hepassocin in the development of non-alcoholic fatty liver disease. Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031 [TBL] [Abstract][Full Text] [Related]
24. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play. Charrez B; Qiao L; Hebbard L World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137 [TBL] [Abstract][Full Text] [Related]
25. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model. Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720 [TBL] [Abstract][Full Text] [Related]
27. Spontaneous onset of nonalcoholic steatohepatitis and hepatocellular carcinoma in a mouse model of metabolic syndrome. Nishida T; Tsuneyama K; Fujimoto M; Nomoto K; Hayashi S; Miwa S; Nakajima T; Nakanishi Y; Sasaki Y; Suzuki W; Iizuka S; Nagata M; Shimada T; Aburada M; Shimada Y; Imura J Lab Invest; 2013 Feb; 93(2):230-41. PubMed ID: 23212097 [TBL] [Abstract][Full Text] [Related]
28. Accumulation of 8-hydroxydeoxyguanosine, L-arginine and Glucose Metabolites by Liver Tumor Cells Are the Important Characteristic Features of Metabolic Syndrome and Non-Alcoholic Steatohepatitis-Associated Hepatocarcinogenesis. Kakehashi A; Suzuki S; Ishii N; Okuno T; Kuwae Y; Fujioka M; Gi M; Stefanov V; Wanibuchi H Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33092030 [TBL] [Abstract][Full Text] [Related]
29. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression? Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736 [TBL] [Abstract][Full Text] [Related]
30. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Dhamija E; Paul SB; Kedia S Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369 [TBL] [Abstract][Full Text] [Related]
35. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma. Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627 [TBL] [Abstract][Full Text] [Related]
36. Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease. Fontes A; Alemany-Pagès M; Oliveira PJ; Ramalho-Santos J; Zischka H; Azul AM Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31426291 [TBL] [Abstract][Full Text] [Related]
37. Non-Alcoholic Fatty Liver Disease. Engin A Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211 [TBL] [Abstract][Full Text] [Related]
38. Insulin resistance and metabolic hepatocarcinogenesis with parent-of-origin effects in A×B mice. Hines IN; Hartwell HJ; Feng Y; Theve EJ; Hall GA; Hashway S; Connolly J; Fecteau M; Fox JG; Rogers AB Am J Pathol; 2011 Dec; 179(6):2855-65. PubMed ID: 21967816 [TBL] [Abstract][Full Text] [Related]
39. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? Scalera A; Tarantino G World J Gastroenterol; 2014 Jul; 20(28):9217-28. PubMed ID: 25071314 [TBL] [Abstract][Full Text] [Related]
40. Analysis of Liver Microenvironment during Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish. Michael C; Martínez-Navarro FJ; de Oliveira S J Vis Exp; 2021 Apr; (170):. PubMed ID: 33871465 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]